Heron Therapeutics Inc

HRTXNASDAQ · USD
0.26USD0.00 (-3.26%)
442

Heron Therapeutics Inc (HRTX) Historical Volatility

HRTX's 30 day historical volatility is 118.18%, in the 76th percentile of readings over the past year. This is a high percentile, meaning Heron Therapeutics Inc shares have swung far more than usual. HRTX's 30 day implied volatility sits at 707.77%, with an IV Rank of 86.51%, leaving IV 589.59 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 18, 2026.

Read more

Tracking HRTX historical volatility helps you see how much Heron Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, HRTX's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor HRTX 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. HRTX's 30 day historical volatility, or HRTX HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing HRTX's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Historical Volatility

HV Percentile
76thHV Percentile
High

Historical movement is elevated versus the past year. The stock has been unusually active.

Historical Volatility (30d)118.18%

HV Percentile76th

Implied Volatility (30d)707.77%

IV Rank86.51%

IV Minus HV+589.59%

As of Nov 18, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 18, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 18, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →